Alethia Young Sells 1,395 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young sold 1,395 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $19,655.55. Following the transaction, the chief financial officer now owns 45,605 shares in the company, valued at approximately $642,574.45. The trade was a 2.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bicycle Therapeutics Trading Down 0.1 %

Bicycle Therapeutics stock traded down $0.01 during trading on Monday, hitting $14.88. The company had a trading volume of 289,310 shares, compared to its average volume of 435,603. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 1-year low of $12.17 and a 1-year high of $28.67. The company’s 50 day simple moving average is $19.27 and its 200-day simple moving average is $21.86.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same period in the previous year, the firm posted ($1.26) earnings per share. The company’s revenue was down 50.0% on a year-over-year basis. As a group, analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on BCYC shares. B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Stephens began coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target for the company. JMP Securities cut their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares during the period. Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics in the 3rd quarter valued at approximately $10,028,000. Geode Capital Management LLC grew its stake in shares of Bicycle Therapeutics by 79.3% in the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after acquiring an additional 16,958 shares in the last quarter. Jane Street Group LLC increased its position in shares of Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after acquiring an additional 5,310 shares during the period. Finally, State Street Corp raised its stake in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.